Abstract:Gastrointestinal cancer has a high incidence in China, especially upper gastrointestinal cancer (esophageal and gastric cancer). Although the incidence has been declining in recent years, the annual incidence of new cases accounts for more than 50% of global cases, and the incidence of colorectal cancer in big cities like Beijing and Shanghai is increasing annually but the mortality rate has not yet increased significantly. Gradual implementation and promotion of multidisciplinary team (MDT) reduced the mortality of gastrointestinal tumors, but this change is not obvious. Successful clinical studies of immune checkpoint inhibitors [programmed death-1 (PD-1), programmed death ligand 1 (PD-L1)] for esophageal and gastric cancer have changed clinical treatment strategies. The overall survival of advanced patients has improved but the comprehensive treatment of locally advanced patients warrants further research. In addition to the microsatellite instability high (MSI-H) population, few drugs have changed the clinical outcome of colorectal cancer in the past decade, which makes it difficult to affect the prognosis of patients. Clinical research on MDT is difficult to conduct, resulting in less data accumulation in this field. The heterogeneity of gastrointestinal tumors is relatively strong and precise treatment should be the direction of future development. In this regard, several studies have been conducted and developed rapidly in recent years in China, including those on MSI-H, human epidermal growth factor receptor 2 (HER2), c-mesenchymal-epithelial transition factor (c-MET), B-Raf proto-oncogene serine/threonine kinase (BRAF), rat sarcoma virus (RAS), fibroblast growth factor receptors (FGFR) and polymerases epsilon (POLE). The selection of immunotherapy markers, as well as the discovery of efficacy and prognostic markers, are also clinicians' concerns. Several articles presented in this issue reflect the research carried out by Chinese researchers based on clinical problems. These concerns of clinicians would impact the clinical practice. However, due to the limitation of time and level, the findings cannot fully reflect the current level of gastrointestinal cancer research in China which is expected to develop rapidly in the future.

Several issues of concern in multidisciplinary treatment for gastric cancer

Updating Advances and Controversies on the Multidisciplinary Therapy of Gastric Cancer

[Multidisciplinary therapy for gastric cancer].

Multidisciplinary Management of Gastric Cancer:Present and Future Status

Several notable issues on standardized treatment of gastric cancer

The foci and problems in diagnosis and treatment of gastric cancer

Improvement of standardized treatment of gastric cancer in China

Progress in Clinical Research of Gastric Cancer

Principle of surgical treatment for gastric cancer:an update

Research Status and Progress on Treatment of Advanced Gastric Cancer

Gastric Carcinoma in China: Current Status and Future Perspectives (Review)

Standardized neoadjuvant chemotherapy for gastric cancer

Nursing perspective of expert consensus for diagnosis and treatment of gastric cancer with integrated traditional Chinese and Western medicine

Multidisciplinary treatment for a patient with locally advanced esophagogastric junc tion cancer

Towards personalized perioperative treatment for advanced gastric cancer.

Treatment of Advanced Gastric Cancer:Current Strategies and Future Perspectives

[New Perspectives on Medical Treatment of Gastric Cancer].

Problems and Countermeasures of Standardized Surgical Treatment for Colorectal Cancer

Current Status and Challenges of Gastrointestinal Cancer Treatment in China

The multidisciplinary management of gastric cancer: Experience from a tertiary comprehensive hospital in Shanghai, China

Pay More Attention to the Standardized Oncologic Assessment of Gastric Cancer Prior to Starting Therapy